PL357246A1 - Związek typu RGD (ARG-GLY-ASP) sprzężony z (neuro)peptydami - Google Patents

Związek typu RGD (ARG-GLY-ASP) sprzężony z (neuro)peptydami

Info

Publication number
PL357246A1
PL357246A1 PL01357246A PL35724601A PL357246A1 PL 357246 A1 PL357246 A1 PL 357246A1 PL 01357246 A PL01357246 A PL 01357246A PL 35724601 A PL35724601 A PL 35724601A PL 357246 A1 PL357246 A1 PL 357246A1
Authority
PL
Poland
Prior art keywords
gly
asp
coupled
arg
rgd
Prior art date
Application number
PL01357246A
Other languages
English (en)
Other versions
PL202279B1 (pl
Inventor
Jong Marion De
Eric Paul Krenning
Hagen Petrus Martinus Van
Original Assignee
Mallinckrodt, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt, Inc. filed Critical Mallinckrodt, Inc.
Publication of PL357246A1 publication Critical patent/PL357246A1/pl
Publication of PL202279B1 publication Critical patent/PL202279B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57563Vasoactive intestinal peptide [VIP]; Related peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/595Gastrins; Cholecystokinins [CCK]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/75Fibrinogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • C07K5/0817Tripeptides with the first amino acid being basic the first amino acid being Arg
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086Bombesin; Related peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/22Tachykinins, e.g. Eledoisins, Substance P; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL357246A 2000-04-26 2001-04-26 Związek typu RGD (ARG-GLY-ASP) sprzężony z (neuro)peptydami PL202279B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00201499 2000-04-26
PCT/EP2001/004764 WO2001081426A2 (en) 2000-04-26 2001-04-26 Rgd (arg-gly-asp) coupled to (neuro)peptides

Publications (2)

Publication Number Publication Date
PL357246A1 true PL357246A1 (pl) 2004-07-26
PL202279B1 PL202279B1 (pl) 2009-06-30

Family

ID=8171409

Family Applications (1)

Application Number Title Priority Date Filing Date
PL357246A PL202279B1 (pl) 2000-04-26 2001-04-26 Związek typu RGD (ARG-GLY-ASP) sprzężony z (neuro)peptydami

Country Status (15)

Country Link
US (1) US7202330B2 (pl)
EP (2) EP1452543A3 (pl)
JP (1) JP2004517034A (pl)
AT (1) ATE272074T1 (pl)
AU (2) AU6898201A (pl)
CA (1) CA2407514C (pl)
CZ (1) CZ20023539A3 (pl)
DE (1) DE60104552T2 (pl)
ES (1) ES2225570T3 (pl)
HU (1) HUP0301571A2 (pl)
IL (1) IL152466A0 (pl)
NO (1) NO20025064L (pl)
NZ (1) NZ522200A (pl)
PL (1) PL202279B1 (pl)
WO (1) WO2001081426A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522200A (en) 2000-04-26 2004-07-30 Biosynthema Inc RGD (ARG-GLY-ASP) coupled to (neuro)peptides
US7122622B2 (en) 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
EP1358890A1 (en) * 2002-05-03 2003-11-05 BioSynthema, Inc Benzothienyl analogue of somatostatine, selective for certain somatostatin receptors
JP4724000B2 (ja) 2003-03-31 2011-07-13 株式会社林原生物化学研究所 ポリペプチド
US20070025910A1 (en) 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy
US7414158B2 (en) 2006-07-24 2008-08-19 The Procter & Gamble Company Process for epimerising cyclohexenyl ketones and its application in Aldol condensation process
KR100987592B1 (ko) * 2008-03-10 2010-10-12 경북대학교 산학협력단 암진단용 mr 조영제와 그 제조방법
CA2720474A1 (en) * 2008-04-04 2009-10-08 Rutgers University Nanocarrier and nanogel compositions
US8263133B2 (en) * 2009-02-18 2012-09-11 The Regents Of The University Of California Multivalent clustering targeting strategy for drug carriers
CN102260352B (zh) * 2010-05-28 2013-11-20 山东先声麦得津生物制药有限公司 靶向性白细胞介素融合蛋白及其制备方法与应用
US9775803B2 (en) 2011-10-19 2017-10-03 Samsung Electronics Co., Ltd. Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof
US9480759B2 (en) 2012-11-21 2016-11-01 Serene, Llc Tin-117m somatostatin receptor binding compounds and methods
HRP20231458T1 (hr) 2017-01-12 2024-05-10 Radiomedix Inc. Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima
CN107412794B (zh) * 2017-04-17 2019-01-04 中国医学科学院北京协和医院 双靶点显像分子探针及其制备方法和应用
CN106967149A (zh) * 2017-05-04 2017-07-21 苏州强耀生物科技有限公司 一种棕榈酰化修饰的半胱氨酸多肽的制备方法
PL238941B1 (pl) * 2018-04-04 2021-10-25 Gdanski Univ Medyczny Związki chemiczne o działaniu przeciwuszkodzeniowym i/lub neuroprotekcyjnym
CN116510033B (zh) * 2023-03-09 2024-03-19 哈尔滨吉象隆生物技术有限公司 一种抗肿瘤的ppc药物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2878341B2 (ja) * 1989-03-03 1999-04-05 学校法人藤田学園 人工機能性ポリペプチド
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
NZ522200A (en) 2000-04-26 2004-07-30 Biosynthema Inc RGD (ARG-GLY-ASP) coupled to (neuro)peptides

Also Published As

Publication number Publication date
PL202279B1 (pl) 2009-06-30
CA2407514C (en) 2011-03-29
CZ20023539A3 (cs) 2003-09-17
AU6898201A (en) 2001-11-07
DE60104552T2 (de) 2005-09-01
US7202330B2 (en) 2007-04-10
AU2001268982B2 (en) 2006-06-15
EP1301540A2 (en) 2003-04-16
US20040136907A1 (en) 2004-07-15
EP1452543A2 (en) 2004-09-01
CA2407514A1 (en) 2001-11-01
DE60104552D1 (de) 2004-09-02
WO2001081426A3 (en) 2002-06-27
HUP0301571A2 (hu) 2003-09-29
ATE272074T1 (de) 2004-08-15
WO2001081426A2 (en) 2001-11-01
NZ522200A (en) 2004-07-30
EP1301540B1 (en) 2004-07-28
ES2225570T3 (es) 2005-03-16
EP1452543A3 (en) 2005-08-03
JP2004517034A (ja) 2004-06-10
IL152466A0 (en) 2003-05-29
AU2001268982B8 (en) 2006-08-03
NO20025064L (no) 2002-12-20
NO20025064D0 (no) 2002-10-22

Similar Documents

Publication Publication Date Title
IL152466A0 (en) RgD (Arg-Gly-Asp) COUPLED TO (NEURO) PEPTIDES
PT1105409E (pt) Proteccao de peptidos terapeuticos endogenos da actividade de peptidases por conjugacao a componentes do sangue
DK1144454T3 (da) Modificerede peptider som terapeutiske midler
WO2001083525A3 (en) Modified peptides, comprising an fc domain, as therapeutic agents
IL131381A0 (en) Therapeutic agent for lymphatic tumors
ATE399177T1 (de) Derivate therapeutischer peptide
WO2003028527A8 (en) Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
EP2298331A3 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
IT1299583B1 (it) Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
AU3739500A (en) Protease resistant flint analogs
WO2001090139A3 (en) A ligand for enhancing oral and cns delivery of biological agents
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
WO2002099379A3 (en) Breast homing peptides and methods of identifying same using aminopeptidase p
CA2315241A1 (en) Protein rim2
JP2002335964A5 (pl)
TW200602353A (en) Modified secretin and method of synthesizing thereof

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20100426